Take a trial of UK to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2009 2010 2011 2012 2013 2014 2015E 2016E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -28.9%

FINANCIAL BRIEF: For the fiscal year ended 31 December 2014, Silence Therapeutics plc revenues decreased 87% to L15K. Net loss increased 23% to L11.1M. Revenues reflect Asia/Japan segment decrease from L103K to L0K. Higher net loss reflects RNAi therapeutics segment loss increase of 60% to L8.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -L0.20 to -L0.22. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Dec '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2015
31st Dec 2016

Price Target: 4.42
(+71.01% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
1 brokers Broker Consensus Trend
Broker Recommendations for Silence Therapeutics
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 0 1

Named Brokers and Analysts
Canaccord Genuity Julie Simmonds , N+1 Singer Jens Lindqvist , Virtua Research (Historical) , and 1 unnamed other

Profile Summary

Silence Therapeutics plc (Silence Therapeutics) is a United Kingdom-based company engaged in the research and development of pharmaceutical products. Silence Therapeutics is engaged in the discovery, development and delivery of ribonucleic acid interference (RNAi) therapeutics for the treatment of diseases. The Company’s products include Atu027, which is in a phase IIa clinical trial and Atu111, which is in Phase I of pre-clinical trial stage. Atu027 is Silence’s leading short interfering RNA (siRNA) therapy. It uses the Company’s AtuPLEX and AtuRNAi technologies to deliver siRNA to the endothelial cells of the vascular system, targeting the expression of the protein PKN3, a key factor in cancer progression and metastasis.

Directors: Alastair Riddell (CHM) 65, Timothy Freeborn (CFO) 54, Lars Karlsson (EDR) 54, Michael Khan (OTH) , Simon Sturge (NED) 56, Stephen Parker (NID) 56,

No. of Employees: 51 No. of Shareholders: n/a

Last Annual December 31st, 2014
Last Interim December 31st, 2014
Incorporated November 18, 1994
Public Since January 5, 2010
Shares in Issue 69,801,624
Free Float 38.5m (55.1%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Intl-aim All Share , FTSE Intl-aim 100 ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

Address 1 Lyric Square/Hammersmith, LONDON, W6 0NB, United Kingdom
Web http://silence-therapeutics.com
Phone +44 20 37009711
Contact Timothy Freeborn (Chief Financial Officer, Finance Director, Secretary, Director)
Auditors PricewaterhouseCoopers LLP

SLN Share Price Performance SLNQuote
-1.5  -0.6%
Traded 4:07pm · Minimum 15 min delayed · NMS: 1.50k

Latest SLN News Announcements (delayed)

Upcoming SLN Events

Recent ↓
Thursday 13th August, 2015
Silence Therapeutics PLC at Canaccord Genuity Growth Conference
Monday 1st June, 2015
Silence Therapeutics PLC Annual Shareholders Meeting
Tuesday 19th May, 2015
Silence Therapeutics PLC at Biocentury BioEquity Europe
Thursday 2nd April, 2015
Silence Therapeutics PLC Secondary Public Offering Pricing
Tuesday 16th September, 2014
Half Year 2014 Silence Therapeutics PLC Earnings Release
Friday 27th June, 2014
Silence Therapeutics PLC Annual Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.

Should you buy SLN

Access SLN Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis